REpeated ASseSsmEnt of SurvivorS in ICH (REASSESS ICH)
ICH 幸存者的重复评估 (REASSESS ICH)
基本信息
- 批准号:10366955
- 负责人:
- 金额:$ 111.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAgeAlteplaseAutomobile DrivingBiological ProcessCerebral Amyloid AngiopathyCerebral hemisphere hemorrhageChronicClinicalClinical TrialsCoagulation ProcessCognitiveComplexDataDementiaDependenceEncephalitisEnrollmentExcisionFollow-Up StudiesFundingGene ExpressionGenesGenotypeHematomaHispanicImpaired cognitionIncidenceInflammationInflammatoryInjuryIschemic StrokeLeukoaraiosisLobarLocationLongitudinal StudiesLongterm Follow-upMethodologyObservational StudyOperative Surgical ProceduresOutcomeOutcome AssessmentOutcome StudyParticipantPathway interactionsPatientsPerformancePersonsRandomized Controlled TrialsReportingResidual stateResidual volumeResourcesRiskRisk FactorsSiteStrokeStructureSuggestionSupratentorialSurvivorsTarget PopulationsTechniquesTelephone InterviewsTestingTimeUnited States National Institutes of HealthVariantVisitaging brainarmcomparativecost effectivedesigndisabilityfollow-upfunctional disabilityfunctional outcomeshigh riskhypertension treatmentimprovedinterestlife time costminimally invasivemortalitymortality riskneuropsychiatrynovelprospectiveracial and ethnicrecruitresponserisk variantsexstandard carestandard of carestroke survivorsurvival outcometreatment strategywhite matter
项目摘要
Project Summary / Abstract
Purpose: The REpeated ASSEssment of SurvivorS in ICH study will conduct long-term cognitive, functional,
and neuropsychiatric performance assessments to determine if evacuation of spontaneous intracerebral
hemorrhage (ICH) reduces the risk of later cognitive decline in the ageing brain. This study will compare rates
of cognitive decline under two treatment strategies for intracerebral hemorrhage: the use of minimally invasive
surgery with two similar techniques as performed in the recently completed MISTIE III and ENRICH trials, and
the current standard of care using data from both controls in MISTIE III and ENRICH and comparative data
from The Ethnic/Racial Variations of ICH (ERICH) study (U-01-NS067963) extended into the ERICH-
Longitudinal study (R01-NS093870) which followed over 900 of the cases with serial cognitive examinations.
Rationale: Intracerebral hemorrhage has the highest disability rate among stroke survivors. ICH survivors are
at particularly high risk for progressive cognitive impairment which is strongly associated with greater
hematoma volume, but also with cerebral amyloid angiopathy. Compared with standard of care, minimally
invasive surgery with effective hematoma volume reduction may improve long-term functional outcomes while
also reducing mortality. As such, reducing hematoma volume after ICH may reduce the risk of post ICH
cognitive decline.
Design: REASSESS ICH is a longitudinal structured serial telephone interview follow-up plus one-time in-
person visit of an anticipated 359 ICH survivors enrolled in MISTIE III (2013-2017) or ENRICH (2018-2022).
Cognitive and functional outcome data will be compared with up to 900 patients enrolled in ERICH-L, to
determine if surgical ICH reduction leads to reduced risk of progressive cognitive decline.
Primary Aim 1: To determine if surgical clot reduction after ICH reduces the risk of progressive cognitive
decline. Hypothesis: The final residual volume of ICH will correlate with risk of cognitive decline after controlling
for age, sex, initial volume of ICH, leukoaraiosis, APOE genotype, and hypertension treatment among operated
and non-operated survivors of MISTIE III/ENRICH and survivors of ERICH, and effective clot reduction (<20
mL end of treatment volume), will be associated with lower risk of cognitive decline compared to non-operated
patients.
Primary Aim 2: To determine if there is a long-term benefit in survival and functional outcome from minimally
invasive surgery and the interaction with cognitive decline. Hypothesis: Effective clot reduction will be
associated with a decreased risk of death/major disability compared to non-operated patients.
Exploratory Aim 3: To determine if inflammatory gene pathway expression predicts risk of cognitive decline.
Hypothesis: Chronic brain inflammation contributes to progressive cognitive impairment post ICH. Our
preliminary data identifies that inflammation appears to occur chronically after ICH; not just acutely. When
testing a wide variety of gene expression changes, the context of which pathway is involved is critical to
provide context. We will evaluate whether inflammatory pathways in particular predict patients with cognitive
impairment independent of gene risk scores for dementia and surgical status.
项目摘要/摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew Flaherty其他文献
Matthew Flaherty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew Flaherty', 18)}}的其他基金
REpeated ASseSsmEnt of SurvivorS in ICH (REASSESS ICH)
ICH 幸存者的重复评估 (REASSESS ICH)
- 批准号:
10545055 - 财政年份:2022
- 资助金额:
$ 111.78万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 111.78万 - 项目类别:
Research Grant